Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.826
AS - Asia 5.882
EU - Europa 5.538
SA - Sud America 967
AF - Africa 86
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 5
Totale 26.316
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.435
SG - Singapore 2.289
CN - Cina 1.375
HK - Hong Kong 1.137
RU - Federazione Russa 1.046
IT - Italia 861
BR - Brasile 796
SE - Svezia 775
IE - Irlanda 728
DE - Germania 633
VN - Vietnam 502
UA - Ucraina 441
GB - Regno Unito 291
CA - Canada 272
FI - Finlandia 173
AT - Austria 159
IN - India 110
FR - Francia 97
TR - Turchia 96
DK - Danimarca 82
AR - Argentina 73
ID - Indonesia 69
MX - Messico 67
RO - Romania 46
JP - Giappone 45
ZA - Sudafrica 45
BD - Bangladesh 43
BE - Belgio 40
IQ - Iraq 38
NL - Olanda 37
PL - Polonia 35
KR - Corea 32
ES - Italia 25
EC - Ecuador 22
CO - Colombia 20
PK - Pakistan 18
IR - Iran 16
CZ - Repubblica Ceca 15
PY - Paraguay 15
SA - Arabia Saudita 15
CL - Cile 14
AE - Emirati Arabi Uniti 12
UZ - Uzbekistan 11
LT - Lituania 10
NP - Nepal 10
VE - Venezuela 10
CR - Costa Rica 9
EU - Europa 9
PA - Panama 9
CH - Svizzera 8
EG - Egitto 8
HN - Honduras 8
PE - Perù 8
DO - Repubblica Dominicana 7
IL - Israele 7
JO - Giordania 7
KE - Kenya 7
MA - Marocco 7
AZ - Azerbaigian 6
OM - Oman 6
PT - Portogallo 6
TN - Tunisia 6
UY - Uruguay 6
JM - Giamaica 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
BH - Bahrain 4
BZ - Belize 4
MY - Malesia 4
TH - Thailandia 4
TW - Taiwan 4
BO - Bolivia 3
GR - Grecia 3
KZ - Kazakistan 3
LB - Libano 3
NG - Nigeria 3
PH - Filippine 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BY - Bielorussia 2
EE - Estonia 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
ML - Mali 2
MN - Mongolia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
BS - Bahamas 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
Totale 26.299
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.412
Woodbridge 1.344
Singapore 1.296
Fairfield 1.231
Hong Kong 1.134
Ashburn 1.041
Houston 1.024
Chandler 745
Dublin 713
Jacksonville 566
Wilmington 546
Seattle 475
Cambridge 435
Frankfurt am Main 404
New York 376
Dearborn 319
Princeton 280
Milan 259
Beijing 212
Dallas 199
Los Angeles 197
Santa Clara 195
Ho Chi Minh City 150
Nanjing 150
Altamura 133
Lawrence 133
Vienna 122
Moscow 118
Shanghai 117
The Dalles 117
Lachine 110
Hanoi 108
Buffalo 94
Chicago 86
São Paulo 86
Hefei 85
Dong Ket 83
San Diego 74
Ottawa 56
Boardman 52
Andover 51
Fremont 51
Jakarta 51
Munich 47
Nanchang 47
Helsinki 44
Galati 43
London 43
Hebei 41
Brussels 40
Shenyang 40
Toronto 38
Nuremberg 34
Salt Lake City 34
Rio de Janeiro 32
Tokyo 32
Guangzhou 31
Hangzhou 29
Norwalk 29
Denver 28
Montreal 27
Seoul 27
Falls Church 25
Tianjin 24
Changsha 23
Columbus 23
Florence 23
Kent 23
Rome 23
San Jose 21
Council Bluffs 20
Phoenix 20
Johannesburg 19
Warsaw 19
Cuauhtémoc 18
Pune 18
Atlanta 17
Edmonton 17
Brasília 16
Stockholm 16
Zhengzhou 16
Boston 15
Jiaxing 15
Kunming 15
Amsterdam 14
Brooklyn 14
Elk Grove Village 14
Mountain View 14
Washington 14
Orem 13
Turku 13
Buenos Aires 12
Baghdad 11
Belo Horizonte 11
Detroit 11
Durban 11
Jinan 11
Miami 11
Quận Bình Thạnh 11
Can Tho 10
Totale 17.737
Salva come PNG Salva come JPEG
Nome #
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 385
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 373
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 306
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 291
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 286
HIV testing: A must for patients with inflammatory bowel disease 281
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 281
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 276
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 271
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 269
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 267
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 265
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 262
Brachial and central blood pressure in HIV-infected subjects 260
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 257
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 256
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 248
Strategies to limit immune-activation in HIV patients 248
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 245
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 240
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 239
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 234
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 233
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 232
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 230
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 227
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 226
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 226
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 225
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 224
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 220
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 217
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 216
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 213
Unmasking tuberculosis in the era of antiretroviral treatment 213
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 212
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 212
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 211
Focal bone lesions in hiv-positive patient treated with tenofovir 210
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 209
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 206
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 205
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 204
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 204
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 204
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 203
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 200
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 198
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 198
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 194
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 194
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 192
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 192
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 191
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 191
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 190
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 189
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 188
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 185
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 184
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 184
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 184
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 183
Effects of antiretroviral therapy on endothelial function in HIV patients. 182
Arterial structure and function in AIDS patients: the impact of renal damage. 180
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 179
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 176
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 174
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 172
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 172
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 171
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 171
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 171
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 171
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 169
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 169
Antimicrobial therapy duration: A major matter in the management of severe infections 168
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 167
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 167
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 166
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 165
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 165
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 164
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 164
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 163
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 163
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 162
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 161
Beyond the gut bacterial microbiota: The gut virome 161
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 160
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 160
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 160
Structural and functional alterations of large arteries in HIV patients and their relationships with metabolic syndrome. 160
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 158
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 157
Impact of HAART with protease inhibitors treatment on carotid wall structure in HIV patients. 155
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 154
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 154
To the editor 153
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme 152
Totale 20.575
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.067
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.093 0 0 0 0 0 119 184 151 162 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20254.704 285 525 358 211 390 156 241 170 571 748 366 683
2025/20265.455 1.129 635 856 1.036 1.270 529 0 0 0 0 0 0
Totale 27.265